Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.6% – Still a Buy?

Eli Lilly and Company (NYSE:LLY) was up 3.6% during mid-day trading on Tuesday. The stock traded as high as $1,311.75 and last traded at $1,285.6060. Approximately 2,956,271 shares changed hands during mid-day trading, an increase of 0% from the average daily volume of 2,947,191 shares. The stock had previously closed at $1,240.34.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs raised its price target to $1,413 from $1,371 and reiterated a Buy rating. The firm reportedly expects Eli Lilly to exceed third-quarter earnings estimates and increase its outlook, supported by stronger international Mounjaro growth and rising Zepbound volume through Medicare’s GLP-1 Bridge program. Eli Lilly Gains 4.6% as Goldman Sachs Lifts Price Target to $1,413
• Positive Sentiment: GLP-1 momentum remains the primary growth catalyst. Investors continue to view Mounjaro and Zepbound as drivers of rapid revenue and earnings growth, while Lilly’s oral obesity treatment Foundayo is reportedly nearing European approval and is expected by Bank of America to gain market share. LLY Stock Hits New Record Ahead of Q3 Earnings
• Positive Sentiment: Positive pediatric ulcerative-colitis data could expand Omvoh’s addressable market. In the Phase 3 SHINE-2 study, 81% of patients responded after induction, and half of responders ages 6–17 achieved clinical remission at Week 52. Lilly plans to submit the results to regulators for a potential label expansion. Lilly’s Omvoh Meets Primary Endpoint
• Positive Sentiment: A new drug-delivery collaboration adds pipeline optionality. Lilly agreed to a potential $1.1 billion deal with Metis TechBio for AI-enabled drug-delivery technology. Metis TechBio Inks Deal With Eli Lilly
• Neutral Sentiment: Earnings are the next major test. Lilly reports third-quarter results on Oct. 29. The stock’s premium valuation and record-high level increase the importance of a meaningful earnings and guidance beat.
• Negative Sentiment: Investors continue to monitor valuation, competition and legal risks. Lilly trades at a substantial premium, faces potential pricing pressure from Novo Nordisk, and is defending a Pennsylvania lawsuit alleging insulin price inflation. These issues could limit upside if GLP-1 growth or future guidance disappoints. Why Is Eli Lilly Being Sued Over Alleged Insulin Price Inflation?

Analysts Set New Price Targets

A number of equities analysts have recently commented on LLY shares. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday. Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Guggenheim increased their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,314.93.

Eli Lilly and Company Stock Performance

The stock’s 50 day moving average price is $1,180.34 and its 200 day moving average price is $1,111.84. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a market capitalization of $1.21 trillion, a P/E ratio of 43.14, a price-to-earnings-growth ratio of 1.67 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 33.56 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several large investors have recently modified their holdings of LLY. BlackRock Inc. boosted its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp grew its stake in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after purchasing an additional 400,538 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.